Physician profile
Rosa E Negron Munoz
NPI 1578720165
$38,757.00
in general payments reported to CMS, 2019-2025
26 companies · $22K in 2025
The $22K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $688 · 2021: $8,086 · 2022: $4,084 · 2023: $856 · 2024: $1,587 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $13K · Travel and Lodging: $7,280 · Food and Beverage: $3,317 · Consulting Fee: $810 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,390.00 |
| Travel and Lodging | $7,279.97 |
| Food and Beverage | $3,317.39 |
| Consulting Fee | $810.00 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| H. Lundbeck A S | $13,390.00 | 2025 | Rexulti |
| Alkermes, INC. | $10,307.46 | 2019-2023 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $8,207.74 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,491.34 | 2019-2025 | Rexulti |
| Abbvie INC. | $1,006.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $658.76 | 2019-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $626.74 | 2020-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $476.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $427.99 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.57 | 2021-2025 | Caplyta |
| Allergan, INC. | $286.78 | 2019-2020 | |
| Tris Pharma INC | $277.95 | 2023-2025 | Dyanavel Xr |
| Neuronetics, INC. | $235.15 | 2020-2022 | |
| Axsome Therapeutics, INC. | $229.32 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $173.55 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $159.80 | 2024-2025 | Rexulti |
| Corium, LLC | $127.92 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $75.75 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $72.03 | 2025 | Fanapt, Hetlioz |
| Tempus Ai, INC | $64.29 | 2024 | |
| Noven Therapeutics, LLC | $50.13 | 2023 | Xelstrym, Secuado |
| Shire North American Group INC | $42.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.09 | 2023 | Qelbree |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Negron Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.